JPWO2020106620A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020106620A5 JPWO2020106620A5 JP2021527208A JP2021527208A JPWO2020106620A5 JP WO2020106620 A5 JPWO2020106620 A5 JP WO2020106620A5 JP 2021527208 A JP2021527208 A JP 2021527208A JP 2021527208 A JP2021527208 A JP 2021527208A JP WO2020106620 A5 JPWO2020106620 A5 JP WO2020106620A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- binding portion
- antibody
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 51
- 102000036639 antigens Human genes 0.000 claims 51
- 108091007433 antigens Proteins 0.000 claims 51
- 150000001413 amino acids Chemical group 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 230000007815 allergy Effects 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000005647 Mumps Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000000621 bronchi Anatomy 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000010063 epididymitis Diseases 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000010805 mumps infectious disease Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229960005347 belatacept Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023072027A JP7587629B2 (ja) | 2018-11-19 | 2023-04-26 | アンタゴニストｃｄ４０モノクローナル抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769514P | 2018-11-19 | 2018-11-19 | |
| US62/769,514 | 2018-11-19 | ||
| PCT/US2019/062011 WO2020106620A1 (en) | 2018-11-19 | 2019-11-18 | Antagonistic cd40 monoclonal antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072027A Division JP7587629B2 (ja) | 2018-11-19 | 2023-04-26 | アンタゴニストｃｄ４０モノクローナル抗体およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022507741A JP2022507741A (ja) | 2022-01-18 |
| JPWO2020106620A5 true JPWO2020106620A5 (https=) | 2022-11-01 |
| JP2022507741A5 JP2022507741A5 (https=) | 2022-11-01 |
| JP7271666B2 JP7271666B2 (ja) | 2023-05-11 |
Family
ID=68848451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527208A Active JP7271666B2 (ja) | 2018-11-19 | 2019-11-18 | アンタゴニストｃｄ４０モノクローナル抗体およびその使用 |
| JP2023072027A Active JP7587629B2 (ja) | 2018-11-19 | 2023-04-26 | アンタゴニストｃｄ４０モノクローナル抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072027A Active JP7587629B2 (ja) | 2018-11-19 | 2023-04-26 | アンタゴニストｃｄ４０モノクローナル抗体およびその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US11261258B2 (https=) |
| EP (1) | EP3883652A1 (https=) |
| JP (2) | JP7271666B2 (https=) |
| KR (1) | KR102627246B1 (https=) |
| CN (2) | CN116003608B (https=) |
| AR (1) | AR117091A1 (https=) |
| AU (2) | AU2019385331B2 (https=) |
| BR (1) | BR112021009140A2 (https=) |
| CA (1) | CA3120358C (https=) |
| CL (1) | CL2021001230A1 (https=) |
| CO (1) | CO2021007691A2 (https=) |
| EA (1) | EA202191359A1 (https=) |
| IL (1) | IL283104B2 (https=) |
| MX (1) | MX2021005565A (https=) |
| MY (1) | MY204740A (https=) |
| PE (1) | PE20211293A1 (https=) |
| SG (1) | SG11202104776VA (https=) |
| TW (1) | TWI800694B (https=) |
| WO (1) | WO2020106620A1 (https=) |
| ZA (1) | ZA202103353B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217976A1 (en) | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| IL300765A (en) * | 2020-08-25 | 2023-04-01 | Bristol Myers Squibb Co | A method for treating an autoimmune disease with antagonistic CD40 monoclonal antibodies |
| FI4284512T3 (fi) | 2021-01-28 | 2025-05-22 | Regeneron Pharma | Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi |
| CN115768477A (zh) * | 2021-06-29 | 2023-03-07 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
| WO2023284714A1 (zh) * | 2021-07-14 | 2023-01-19 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
| EP4506364A4 (en) * | 2022-04-02 | 2026-04-22 | Harbour Biomed Shanghai Co Ltd | CD40 TARGETED ANTIGEN BINDING PROTEIN, ITS PREPARATION AND USE |
| CN117264063B (zh) * | 2023-03-22 | 2024-04-23 | 赛业（苏州）生物科技有限公司 | 一种抗gpc3抗体及其应用 |
| CN119490596B (zh) * | 2023-08-21 | 2026-01-23 | 菲鹏生物股份有限公司 | 一种抗人IgM抗体及其应用 |
| KR20250116195A (ko) * | 2024-01-24 | 2025-08-01 | 서울대학교산학협력단 | Cd40에 특이적으로 결합하는 항체 및 이의 용도 |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025235683A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
| WO2025235670A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| GB2353887B (en) | 1999-09-04 | 2003-09-24 | Ibm | Speech recognition system |
| WO2003028809A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Methods of therapy for b-cell malignancies |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| CA2544951A1 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
| PT1694360E (pt) * | 2003-11-04 | 2010-12-13 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos |
| ATE474598T1 (de) * | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| CN101014386A (zh) * | 2004-04-27 | 2007-08-08 | 诺华疫苗和诊断公司 | 拮抗性抗－cd40单克隆抗体及其使用方法 |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| US20150315284A1 (en) | 2004-11-09 | 2015-11-05 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| EP1888098A2 (en) | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| KR20080073293A (ko) | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| EP2125893A2 (en) | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| AU2008247819B2 (en) | 2007-05-01 | 2013-02-14 | Research Development Foundation | Immunoglobulin Fc libraries |
| ES2572356T3 (es) | 2007-11-09 | 2016-05-31 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpos dirigidos contra VEGF y procedimientos |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| BR112012024713B1 (pt) | 2010-03-31 | 2021-02-17 | Boehringer Ingelheim International Gmbh | anticorpo humanizado, seus usos e composição farmacêutica que o compreende |
| WO2012046745A1 (ja) | 2010-10-04 | 2012-04-12 | 独立行政法人理化学研究所 | Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| BR112013026828A2 (pt) | 2011-04-21 | 2016-11-29 | Bristol Myers Squibb Co | polipeptídeos de anticorpo que antagonizam cd40 |
| CN113461819B (zh) | 2011-04-29 | 2024-01-02 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| EP3680251A1 (en) | 2011-09-30 | 2020-07-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules for promoting elimination of antigens |
| JP6226752B2 (ja) | 2012-02-09 | 2017-11-08 | 中外製薬株式会社 | 抗体のＦｃ領域改変体 |
| GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| TW202237660A (zh) | 2012-08-24 | 2022-10-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| AU2013337903B2 (en) * | 2012-10-30 | 2018-08-16 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| GB201308658D0 (en) | 2013-05-14 | 2013-06-26 | Isis Innovation | Antibodies |
| WO2015134988A1 (en) | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| JP6464255B2 (ja) | 2014-08-04 | 2019-02-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｔ細胞活性化抗原結合分子 |
| KR20170035945A (ko) * | 2014-08-14 | 2017-03-31 | 에프. 호프만-라 로슈 아게 | 인간 cd40을 활성화시키는 항체 및 인간 pd-l1에 대한 항체의 병용 요법 |
| US20170233485A1 (en) * | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| US10174121B2 (en) | 2015-05-29 | 2019-01-08 | Abbvie, Inc. | Anti-CD40 antibodies |
| HK1252666A1 (zh) * | 2015-06-29 | 2019-05-31 | Bristol-Myers Squibb Company | 针对cd40的抗体 |
| AU2016285920A1 (en) | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
| CR20180177A (es) | 2015-09-30 | 2018-06-22 | Janssen Biotech Inc | Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso |
| JP7471819B2 (ja) | 2016-10-06 | 2024-04-22 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 工程不純物への結合が低下している抗体 |
| KR102715540B1 (ko) | 2017-03-14 | 2024-10-08 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| US20200095323A1 (en) | 2017-03-20 | 2020-03-26 | The General Hospital Corporation | MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY |
| KR20200012907A (ko) | 2017-05-25 | 2020-02-05 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체 |
| IL270596B2 (en) | 2017-05-25 | 2026-01-01 | Bristol Myers Squibb Co | Antibodies containing heavy constant regions are adapted for use in cancer therapy |
| WO2018217976A1 (en) | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
| AU2018361743A1 (en) | 2017-11-03 | 2020-04-09 | Novartis Ag | Anti-CD40 antibodies for use in treatment of Sjogren's syndrome |
| EP3880231A1 (en) | 2018-11-16 | 2021-09-22 | NeoImmuneTech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
-
2019
- 2019-11-15 AR ARP190103362A patent/AR117091A1/es unknown
- 2019-11-18 JP JP2021527208A patent/JP7271666B2/ja active Active
- 2019-11-18 US US16/686,596 patent/US11261258B2/en active Active
- 2019-11-18 PE PE2021000727A patent/PE20211293A1/es unknown
- 2019-11-18 SG SG11202104776VA patent/SG11202104776VA/en unknown
- 2019-11-18 MY MYPI2021002555A patent/MY204740A/en unknown
- 2019-11-18 BR BR112021009140-8A patent/BR112021009140A2/pt not_active Application Discontinuation
- 2019-11-18 CN CN202310098945.0A patent/CN116003608B/zh active Active
- 2019-11-18 WO PCT/US2019/062011 patent/WO2020106620A1/en not_active Ceased
- 2019-11-18 IL IL283104A patent/IL283104B2/en unknown
- 2019-11-18 EP EP19818398.0A patent/EP3883652A1/en active Pending
- 2019-11-18 CN CN201980076479.8A patent/CN113164781B/zh active Active
- 2019-11-18 EA EA202191359A patent/EA202191359A1/ru unknown
- 2019-11-18 MX MX2021005565A patent/MX2021005565A/es unknown
- 2019-11-18 CA CA3120358A patent/CA3120358C/en active Active
- 2019-11-18 KR KR1020217018573A patent/KR102627246B1/ko active Active
- 2019-11-18 AU AU2019385331A patent/AU2019385331B2/en active Active
- 2019-11-19 TW TW108142021A patent/TWI800694B/zh active
-
2020
- 2020-10-26 US US17/080,626 patent/US11254750B2/en active Active
-
2021
- 2021-05-11 CL CL2021001230A patent/CL2021001230A1/es unknown
- 2021-05-18 ZA ZA2021/03353A patent/ZA202103353B/en unknown
- 2021-06-11 CO CONC2021/0007691A patent/CO2021007691A2/es unknown
-
2022
- 2022-01-19 US US17/579,468 patent/US11926673B2/en active Active
- 2022-01-31 US US17/588,518 patent/US11773178B2/en active Active
- 2022-02-11 US US17/670,223 patent/US11795231B2/en active Active
-
2023
- 2023-04-26 JP JP2023072027A patent/JP7587629B2/ja active Active
- 2023-08-22 US US18/453,691 patent/US12409223B2/en active Active
-
2024
- 2024-02-14 US US18/441,998 patent/US12419953B2/en active Active
-
2025
- 2025-01-17 AU AU2025200355A patent/AU2025200355A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101513498B1 (ko) | 항―ｎｋｇ2ａ 항체 및 이들의 용도 | |
| JP7118480B2 (ja) | 抗ヒトインターロイキン－４受容体αのモノクローナル抗体およびその使用 | |
| AU2012245309B2 (en) | Antibody polypeptides that antagonize CD40 | |
| TWI339209B (en) | Human antibodies that bind human il-12 and methods for producing | |
| TWI373343B (en) | Antibodies that bind human interleukin-18 and methods of making and using | |
| RU2577228C2 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| JPWO2020106620A5 (https=) | ||
| JP3920215B2 (ja) | ヒトｍｃｐ−１に対する抗体 | |
| JP2019162105A5 (https=) | ||
| TW201138825A (en) | TNF-α binding proteins | |
| JP2023113636A5 (https=) | ||
| JP2020509756A5 (https=) | ||
| KR100872210B1 (ko) | 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체 | |
| KR20150029002A (ko) | 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법 | |
| CN105936648A (zh) | Cd28结合为单价的组合物及使用方法 | |
| WO2010055366A4 (en) | Anti-human il-21 monoclonal antibodies | |
| WO2013039954A1 (en) | Anti-gitr antibodies | |
| CN103154029A (zh) | 抗人tweak的抗体及其用途 | |
| TWI423815B (zh) | 抗人類ｔｗｅａｋ抗體及其用途 | |
| EP4522652A1 (en) | Anti-tl1a antibodies and methods of use thereof | |
| JP2019081766A (ja) | インターフェロンアルファ及びオメガ抗体アンタゴニスト | |
| JP2019531063A (ja) | インターロイキン−６のヒト受容体に結合することができる抗体またはその抗原結合フラグメント | |
| KR20230117178A (ko) | T 세포 인게이저 치료제의 개발 및 적용 | |
| JP2015533374A5 (https=) | ||
| US12516121B2 (en) | Antibodies to human programmed death receptor PD-1 |